patent semaglutide Novo Nordisk expiry opens door to cheaper weight-loss drugs in India Indian pharma launches low-cost Ozempic

At approximately $1,999 per month through MEDVi, this option is significantly more expensive and primarily appeals to patients whose insurance does not cover weight loss medications but who still want the assurance of a brand-name, FDA-approved product

Over an average of about three years, semaglutide 2.4 mg reduced major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) by 20% compared to placebo

Exp Mol Pathol (2021) 119:104617

Additionally, some OTC alternatives may contain stimulants or unapproved compounds that can pose health risks, particularly for individuals with underlying medical conditions